{
    "clinical_study": {
        "@rank": "65599", 
        "arm_group": {
            "arm_group_label": "Trastuzumab and weekly chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly  trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.\nAfter completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
        }, 
        "brief_summary": {
            "textblock": "There is major concern regarding chemotherapy related toxicity in the group of women older\n      than 65 years old diagnosed with human epidermal growth factor receptor 2 (HER2) positive\n      breast cancer (BC). Nevertheless, these patients are at a particularly high risk of breast\n      cancer recurrence and death. Of note, older patients may experience higher risk for\n      Trastuzumabe related cardiotoxicity, especially when this agent is combined with an\n      anthracycline.\n\n      Recent studies have shown extremely favourable outcomes in early HER2+ BC patients treated\n      with a combination of paclitaxel and trastuzumab, omitting anthracyclines from treatment.\n\n      Investigators sought to investigate safety and outcome data on a cohort of elderly patients\n      treated with weekly paclitaxel combined with carboplatin and trastuzumab."
        }, 
        "brief_title": "Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Elderly Patients Diagnosed With Breast Cancer", 
            "HER-2 Positive Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Breast cancer is the most common female cancer and the second most common cause of cancer\n      death in women.  BC incidence is markedly increased with aging.\n\n      Amplification or overexpression of HER2 oncogene is present in approximately 18 to 20% of\n      primary invasive BC. In the absence of HER2 target therapy combined with adjuvant or\n      neoadjuvant chemotherapy, HER2 overexpression or amplification is associated with high rates\n      of disease recurrence and death.\n\n      There is major concern regarding chemotherapy related toxicity in the group of women older\n      than 65 years old diagnosed with HER2 positive breast cancer. Nevertheless, these patients\n      are at a particularly high risk of breast cancer recurrence and death. Of note, older\n      patients may experience higher risk for Trastuzumabe related cardiotoxicity, especially when\n      this agent is combined with an anthracycline.\n\n      Recent studies have shown extremely favourable outcomes in early HER2+ BC patients treated\n      with a combination of paclitaxel and trastuzumab, omitting anthracyclines from treatment.\n\n      Investigators sought to investigate safety and outcome data on a cohort of elderly patients\n      treated with weekly paclitaxel combined with carboplatin and trastuzumab."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical or Pathological Stage I- IIIA breast adenocarcinoma.\n\n          -  HER2 overexpression or amplification defined by immunohistochemistry staining of +3\n             or positive fluorescence in situ hybridization (FISH) test.\n\n          -  Age \u2265 65 years old.\n\n          -  WHO performance status less than 2; adequate hematologic (granulocyte count \u2265 2 X\n             109/L, platelet count \u2265100 X109/L) and hepatic (transaminases \u2264 1.5 X the upper limit\n             of normal (ULN), alkaline phosphatases \u2264 2.5 times ULN, and bilirubin \u2264 ULN) tests;\n             and normal cardiac function (baseline left ventricular ejection fraction at least \u2265\n             55%)\n\n        Exclusion Criteria:\n\n          -  Radiologic imaging of metastatic disease.\n\n          -  History of cardiac disease contraindicating anthracyclines, uncontrolled essential\n             hypertension or diabetes, stroke or any other comorbidity that could potentially\n             compromise chemotherapy treatment, such as chronic obstructive pulmonary disease.\n\n          -  Any previous treatment with anti HER2 therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102438", 
            "org_study_id": "NP 477"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trastuzumab and weekly chemotherapy", 
                "description": "Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.\nAfter completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles.", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Trastuzumab", 
                    "Other names", 
                    "Herceptin"
                ]
            }, 
            {
                "arm_group_label": "Trastuzumab and weekly chemotherapy", 
                "description": "Weekly paclitaxel  at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.", 
                "intervention_name": "Weekly Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }, 
            {
                "arm_group_label": "Trastuzumab and weekly chemotherapy", 
                "description": "Carboplatin at an Area Under the Curve (AUC) of 2  at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Other names", 
                    "Paraplatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trastuzumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Elderly patients", 
            "Localized HER2+ Breast Cancer", 
            "Omission of anthracyclines", 
            "Neoadjuvant chemotherapy", 
            "Adjuvant chemotherapy", 
            "Safety information"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "zip": "01246-000"
                }, 
                "name": "ICESP"
            }, 
            "investigator": {
                "last_name": "Debora Gagliato, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Neoadjuvant or Adjuvant Chemotherapy Without Anthracyclines for Elderly Patients Diagnosed With HER2 Positive Breast Cancer", 
        "overall_contact": {
            "email": "dgagliato@gmail.com", 
            "last_name": "Debora de Gagliato, MD", 
            "phone": "55 11 971002395"
        }, 
        "overall_contact_backup": {
            "email": "max.mano@gmail.com", 
            "last_name": "Max Mano, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "last_name": "Debora de Gagliato, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "last_name": "Max Se Mano, MD phD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease Free Survival was defined as the time from randomization until first relapse (local, regional, or distant), contralateral breast cancer, or death from any cause.", 
            "measure": "Disease Free Survival (DFS)", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102438"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary end points are overall survival (OS), defined from the time from randomization until death from any cause, and safety.", 
            "measure": "survival (OS)", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}